- Home
- FE vs BDTX Comparison
FE vs BDTX Comparison
Compare FE & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FE
- BDTX
- Stock Information
- Founded
- FE 1996
- BDTX 2014
- Country
- FE United States
- BDTX United States
- Employees
- FE N/A
- BDTX N/A
- Industry
- FE Electric Utilities: Central
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FE Utilities
- BDTX Health Care
- Exchange
- FE Nasdaq
- BDTX Nasdaq
- Market Cap
- FE 23.9B
- BDTX 181.4M
- IPO Year
- FE N/A
- BDTX 2020
- Fundamental
- Price
- FE $43.62
- BDTX $3.19
- Analyst Decision
- FE Buy
- BDTX Strong Buy
- Analyst Count
- FE 16
- BDTX 6
- Target Price
- FE $46.14
- BDTX $12.50
- AVG Volume (30 Days)
- FE 3.3M
- BDTX 805.6K
- Earning Date
- FE 10-28-2025
- BDTX 11-04-2025
- Dividend Yield
- FE 4.07%
- BDTX N/A
- EPS Growth
- FE 49.18
- BDTX N/A
- EPS
- FE 2.27
- BDTX 0.25
- Revenue
- FE $13,864,000,000.00
- BDTX $70,000,000.00
- Revenue This Year
- FE $8.73
- BDTX N/A
- Revenue Next Year
- FE $3.41
- BDTX N/A
- P/E Ratio
- FE $19.27
- BDTX $12.74
- Revenue Growth
- FE 6.52
- BDTX N/A
- 52 Week Low
- FE $37.58
- BDTX $1.20
- 52 Week High
- FE $44.78
- BDTX $6.23
- Technical
- Relative Strength Index (RSI)
- FE 56.78
- BDTX 60.41
- Support Level
- FE $42.87
- BDTX $2.56
- Resistance Level
- FE $43.81
- BDTX $3.43
- Average True Range (ATR)
- FE 0.47
- BDTX 0.17
- MACD
- FE -0.06
- BDTX 0.04
- Stochastic Oscillator
- FE 70.62
- BDTX 67.57
About FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with 10 regulated distribution utilities across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.